Using AI to predict light chain amyloidosis in patients with MGUS and SMM
10 Visninger
• 11/23/23
0
0
Indlejre
administrator
Abonnenter
Eli Muchtar, MD, Mayo Clinic, Rochester, MN, comments on the potential of artificial intelligence (AI) in predicting the risk of developing AL amyloidosis in patients with multiple myeloma precursor conditions such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.
Vis mere
Facebook kommentarer
SORT BY-
Topkommentarer
-
Seneste kommentarer